Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL
- 174 Downloads
Results of recent studies have confirmed the efficacy of an 8-week course of ledipasvir/sofosbuvir (LDV/SOF) in patients who are non-cirrhotics, native to treatment, are infected with hepatitis C (HCV) genotype 1, and have HCV viral load < 6 million IU/mL. However, there are limited data on a shortened treatment course in patients who are over the age of 65.
A retrospective study was performed to examine the safety, tolerability, and sustained viral response rates (SVR) of the 8-week LDV/SOF therapy compared to the 12-week LDV/SOF therapy among non-cirrhotic, treatment-naïve, genotype 1 HCV patients with viral load < 6 million IU/mL who are 65 years of age or older.
A total of 454 patients were identified of which 182 non-cirrhotic, genotype 1 HCV-RNA < 6 million IU/mL patients received the 8-week LDV/SOF treatment and 272 received the 12-week LDV/SOF treatment. Mean [± standard deviation (SD)] aspartate aminotransferase to platelet ratio index score for the entire cohort was 0.45 ± 0.03. The mean (± SD) age for the 8-week treatment was 69.7 (± 7) years, 54.7% male and 45.3% female. The mean (± SD) age of the 12-week treatment was 71.7 (± 3) years, 56.4% male and 43.6% female. Overall, SVR-12 for the 8-week regimen was 93% and SVR-12 for the 12-week regimen was 95%. For the 182 treated with the 8-week LDV/SOF treatment, there were no serious adverse events requiring hospitalization or signs of liver failure requiring transplantation. Overall, the 8-week treatment patient cohort experienced less fatigue, headache, dry mouth, and diarrhea. This finding was statistically significant with a P value < 0.001.
Eight-week LDV/SOF therapy in treatment-naive, non-cirrhotic, genotype 1 HCV patients with RNA < 6 million IU/mL was found safe, better tolerated, effective, and required less upfront cost when compared with the 12-week LDV/SOF treatment regimen in properly selected geriatric population.
KeywordsHepatitis C Sustained viral response Ledipasvir/sofosbuvir
Hepatitis C virus
Direct acting antiviral
Sustained viral response at 12 weeks post-treatment with direct acting antiviral agents for hepatitis C
Aspartate aminotransferase to platelet ratio index
Human immunodeficiency virus
Electronic medical record
BY, SA, and SS conceived and designed the study; BY and NL helped in acquisition of data; BY, NL, and SS analyzed and interpreted the data; BY, AM, MM, RH, and AA drafted the manuscript; BY, AS, FD, and SS critically revised the manuscript for important intellectual content; NL and BY performed the statistical analysis; BY, AS, SS, and FD contributed to administrative, technical, or material support and study supervision.
Compliance with ethical standards
Conflict of interest
The authors have no conflict of interest or disclosures to declare.
- 2.Latt N, Yanny B, Gharibian D, Gevorkyan R, Sahota A. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety. World J Gastroenterol. 2017;23:4759–4766.CrossRefPubMedGoogle Scholar
- 12.Rheem J, Sundaram V, Saab S. Antiviral therapy in elderly patients with hepatitis C virus infection. Gastroenterol Hepatol (NY). 2015;11:294–346.Google Scholar
- 13.Ansari U, Henderson LI, Stott G, Parr K. Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus. J Am Acad Dermatol. 2017;3:67–69.Google Scholar
- 32.Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol. 2015;15:217–220.Google Scholar
- 33.American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2017. http://www.hcvguidelines.org/full-report/initial-treatment-hcv-infection. Accessed July 2017.
- 35.Harvoni (ledipasvir and sofosbuvir) tablet product information. Foster City, CA: Gilead Sciences, Inc.; 2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205834s001lbl.pdf. Accessed July 2017.